Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy
PHASE2CompletedINTERVENTIONAL
Enrollment
55
Participants
Timeline
Start Date
Not specified
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG
CHOP21-R
Four months for CHOP21-R and two treatment days one week apart
DRUG
Zevalin
12-week safety period for Zevalin
Trial Locations (1)
40138
Istituto di Ematologia e Oncologia Medica Seràgnoli, Bologna
All Listed Sponsors
lead
University of Bologna
OTHER
NCT00850512 - Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy | Biotech Hunter | Biotech Hunter